216 related articles for article (PubMed ID: 34983745)
1. Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti-PD-1 Therapy.
Wang K; Patkar S; Lee JS; Gertz EM; Robinson W; Schischlik F; Crawford DR; Schäffer AA; Ruppin E
Cancer Discov; 2022 Apr; 12(4):1088-1105. PubMed ID: 34983745
[TBL] [Abstract][Full Text] [Related]
2. KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.
Xie K; Peng Y; Zhong W; Liu X
Front Biosci (Landmark Ed); 2022 Mar; 27(3):103. PubMed ID: 35345335
[TBL] [Abstract][Full Text] [Related]
3. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
[TBL] [Abstract][Full Text] [Related]
6. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
7. Deactivation of ligand-receptor interactions enhancing lymphocyte infiltration drives melanoma resistance to Immune Checkpoint Blockade.
Sahni S; Wang B; Wu D; Dhruba SR; Nagy M; Patkar S; Ferreira I; Wang K; Ruppin E
bioRxiv; 2023 Sep; ():. PubMed ID: 37886558
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
[TBL] [Abstract][Full Text] [Related]
10. Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.
Krijgsman O; Kemper K; Boshuizen J; Vredevoogd DW; Rozeman EA; Ibanez Molero S; de Bruijn B; Cornelissen-Steijger P; Shahrabi A; Del Castillo Velasco-Herrera M; Song JY; Ligtenberg MA; Kluin RJC; Kuilman T; Ross-Macdonald P; Haanen JBAG; Adams DJ; Blank CU; Peeper DS
Clin Cancer Res; 2021 Oct; 27(19):5389-5400. PubMed ID: 34230026
[TBL] [Abstract][Full Text] [Related]
11. Performance of tumour microenvironment deconvolution methods in breast cancer using single-cell simulated bulk mixtures.
Tran KA; Addala V; Johnston RL; Lovell D; Bradley A; Koufariotis LT; Wood S; Wu SZ; Roden D; Al-Eryani G; Swarbrick A; Williams ED; Pearson JV; Kondrashova O; Waddell N
Nat Commun; 2023 Sep; 14(1):5758. PubMed ID: 37717006
[TBL] [Abstract][Full Text] [Related]
12. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
13. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
14. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
15. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
16. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
17. TimiGP: Inferring cell-cell interactions and prognostic associations in the tumor immune microenvironment through gene pairs.
Li C; Zhang B; Schaafsma E; Reuben A; Wang L; Turk MJ; Zhang J; Cheng C
Cell Rep Med; 2023 Jul; 4(7):101121. PubMed ID: 37467716
[TBL] [Abstract][Full Text] [Related]
18. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
19. Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma.
Thrane K; Eriksson H; Maaskola J; Hansson J; Lundeberg J
Cancer Res; 2018 Oct; 78(20):5970-5979. PubMed ID: 30154148
[TBL] [Abstract][Full Text] [Related]
20. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Danilova L; Wang H; Sunshine J; Kaunitz GJ; Cottrell TR; Xu H; Esandrio J; Anders RA; Cope L; Pardoll DM; Drake CG; Taube JM
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7769-E7777. PubMed ID: 27837027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
